Trial Profile
Phase I/II Study of Combination Everolimus (RAD001), and Rituximab (Rituxan), OR Everolimus, Bortezomib (Velcade, PS-341), and Rituximab in Patients With Relapsed and/or Relapsed/Refractory Waldenstrom's Macroglobulinemia
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Everolimus (Primary) ; Rituximab
- Indications Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 22 Apr 2021 According to clinicaltrials.gov the study was discontinued because as per the protocol, phase II is to be terminated early if a less than 5% of the Phase II participants observe a Very Good Partial Response or Better in the first 23 participants enrolled to Phase II.
- 22 Apr 2021 Status changed from active, no longer recruiting to discontinued.
- 01 Nov 2018 Planned End Date changed from 1 Jan 2018 to 1 Feb 2020.